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Purpose: The aim of this study was to determine quantitative changes in selected species of bacteria (Bacteroides 
fragilis, Lactobacillus fermentum, Lactobacillus rhamnosus, Serratia marcescens) in the stool of patients with Crohn's 
disease (CD) in the course of induction treatment with exclusive enteral nutrition (EEN) or anti-tumor necrosis 
factor alpha (Infliximab, IFX) vs. healthy controls (HC). 
Materials/methods: DNA was isolated from stool samples of CD (n = 122) and HC (n = 17), and quantitative 
real-time Polymerase Chain Reaction (qPCR) was applied. In both treatment groups, the first stool sample was 
taken before the start of treatment, and the second 4 weeks after its end: in EEN (n = 48; age (mean; SD) 
13.35  ±  3.09 years) and IFX groups (n = 13; age (mean; SD) 13.09  ±  3.76 years). 
Results: The only species that showed a statistically significant difference between the two groups of patients 
before any therapeutic intervention was L. fermentum. Moreover, its number increased after completion of EEN 
and differed significantly when compared with the HC. In the IFX group the number of L. fermentum decreased 
during the therapy but was significantly higher than in the HC. The number of S. marcescens in the EEN group 
was significantly lower than in the controls both before and after EEN. 
Conclusion: The implemented treatment (EEN or IFX) modifies the microbiome in CD patients, but does not 
make it become the same as in HC.   
1. Introduction 
Over the past few years, there has been an increase in incidence of 
inflammatory bowel disease (IBD), including Crohn's disease (CD), in 
younger age groups all over the world, particularly in newly in-
dustrialized European countries, now following the so-called Western 
pattern diet [1,2]. 
The IBD etiology is extremely complex and still not fully explained. 
The intestinal microbiome, especially the disturbance of the balance in 
the composition of gastrointestinal microorganisms (dysbiosis), seems 
to be an important mechanism in the induction and maintenance of 
inflammation in CD patients [3]. Numerous studies indicate the asso-
ciation between a reduced number of Gram-positive bacteria and, 
probably compensatory, increased numbers of Gram-negative bacteria 
and the occurrence of CD [4]. It is likely that lipopolysaccharide (LPS), 
a component of the cell wall of Gram-negative bacteria, is involved in 
the development of the disease, probably through the effect on the 
immune system and the stimulation of inflammation [5,6]. The better 
knowledge on the influence of particular species of bacteria on the 
course of CD could help to develop individual therapies aimed at the 
modification of the composition of microbial guts, and thus, the alle-
viation or elimination of inflammation [7]. 
The principles of the treatment of pediatric patients are based on the 
recommendations of the European Crohn's and Colitis Organisation 
(ECCO) and European Society of Pediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) [8]. In newly diagnosed CD pa-
tients with mild to moderate disease activity, the exclusive enteral 
nutrition therapy (EEN) is the first choice of treatment. For 6–8 weeks, 
the patient's diet consists only of standard, liquid, polymeric formulas 
and is followed by pharmacological treatment with thiopurines or 
methotrexate (conventional therapy) and mesalazine to maintain re-
mission [8]. Patients with high activity of CD and those who failed to 
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respond to conventional therapy are candidates for biological therapy, 
e.g. with anti-tumor necrosis factor alpha. Infliximab (IFX) is used as a 
first-line biologic agent in pediatric CD. Doses of 5 mg/kg are given 
intravenously in 0-, 2- and 6-week modes as induction therapy, and 
then every 8 weeks as a maintenance treatment [9]. 
To enhance the current knowledge of the contribution of intestinal 
bacteria to CD development, we analyzed the relationship between the 
number of selected species of colorectal bacteria and the type of 
treatment implemented (EEN or IFX) in CD patients compared with 
control group. To determine the number of bacteria we used a highly 
specific, quantitative Polymerase Chain Reaction (qPCR) test. We also 
attempted to assess the association between the number of bacteria and 
basic biochemical parameters in patients from the studied groups. Due 
to the complexity of the role of microbiome in CD development and 
richness of the microorganisms involved, and thus the technical re-
quirements for their identification, only 4 of the most important bac-
terial species were assessed in the study: 2 species of Gram-positive 
bacteria, as representatives of microorganisms with probiotic properties 
(Lactobacillus fermentum and Lactobacillus rhamnosus) [10] and 2 species 
of Gram-negative bacteria, commonly occurring in the environment, 
and under certain conditions, considered potentially pathogenic to 
humans (Bacteroides fragilis and Serratia marcescens) [11,12]. 
2. Material and methods 
Children from 2 to 18 years of age, diagnosed with CD according to 
the revised Porto criteria [13], hospitalized at the Department of Pe-
diatrics, Gastroenterology and Nutrition, University Children's Hospital 
in Krakow, Poland, between the years 2015-2018, were recruited into 2 
groups. The first group consisted of 48 patients with newly diagnosed 
CD who received EEN for 6 weeks as the induction of remission. In this 
group, we obtained the first stool sample before treatment and the 
second sample 3–4 weeks after completion of EEN. In the second group, 
there were 13 CD patients who received IFX (Remsima®, Celltrion 
Healthcare, Incheon, South Korea) because they failed to respond or 
became unresponsive to the conventional maintenance treatment with 
thiopurines or methotrexate. In this group, IFX was given intravenously 
in standard 0-, 2- and 6-week modes as induction therapy, and the first 
stool sample was obtained before the first dose of IFX and the second 4 
weeks after the third induction dose of IFX. The control group com-
prised 17 healthy, unrelated children, who did not meet exclusion 
criteria and from whom only one stool sample was obtained. 
Exclusion criteria included: age below 2 or over 18 years, treatment 
with antibiotics and/or probiotics 3 months before collecting fecal 
samples, confirmed acute or chronic gastrointestinal infections, active 
neoplastic disease, congenital and/or acquired immune deficiencies and 
lack of consent to be included in the study. 
The stool samples collected into sterile containers at hospital (pa-
tients) or at home (controls) were stored under refrigerated conditions 
for up to 24 h, and then kept deep-frozen (−70 °C) until analysis was 
done. All CD patients underwent also routine hematological and bio-
chemical testing (erythrocyte sedimentation rate, glucose, serum al-
bumin, protein and iron concentration). The blood samples were taken 
at the same time points as the stool samples. The activity of the disease 
was evaluated by using Pediatric Crohn's Disease Activity Index 
(PCDAI; maximal score: 100 points; 0–10 points – inactive disease, 
10–30 points – mild disease, > 30 points – moderate to severe disease). 
2.1. Ethical issues 
The protocol of the study was approved by Jagiellonian University 
Ethics Committee in Krakow, Poland (decisions numbers: 
122.6120.67.2015 and 122.6120.68.2015 from 30.04.2015).All per-
formed procedures were in accordance with the 1964 Helsinki de-
claration and its later amendments. Informed consent was signed by 
patients' parents or legal guardians (for all patients under 18 years of 
age) and, in addition by patients themselves, if above 16 years old. 
2.2. DNA extraction from the stool samples 
In this study, a modified procedure by Kowalska-Duplaga et al. [14] 
was used for DNA extraction. Bacterial DNA was isolated from 139 fecal 
samples using Genomic Mini AX Stool Spin (A&A Biotechnology, 
Gdansk, Poland) while applying the preliminary procedure developed 
by Gosiewski et al. [15]. The next steps of DNA extraction were carried 
out according to the A&A Biotechnology's procedure. 
2.3. Quantitative real-time PCR (qPCR) 
The extracted DNA was quantitatively examined for the following 
selected bacteria: B. fragilis, L. fermentum, L. rhamnosus, and S. marces-
cens by qPCR using the CFX96 thermocycler (BioRad, California, USA). 
Table 1 
Primer sequences of selected species of bacteria and thermal amplification programs used in the study.      
Target species Primer sequence 5’→ 3′ Reference Thermal amplification 
program  
Bacteroides fragilis (F)TCRGGAAGAAAGCTTGCT 
(R)CATCCTTTACCGGAATCCT 
[29] 95 °C – 5 min 
Lactobacillus fermentum (F)AACCGAGACCACCGCGTTAT 
(R)ACTTAACCTTACTGATCGTAGATCAGTC 
[25] 95 °C – 5 min 
Lactobacillus rhamnosus (F)CGGCTGGATCACCTCCTTT 
(R)GCTTGAGGGTAATCCCCTCAA 
[30] 95 °C – 5 min 
Serratia marcescens (F)TGCCTGGAAAGCGGCGATGG 
(R) CGCCAGCTCGTCGTTGTGGT 
[22] 95 °C – 5 min 
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To detect specific DNA sequences, ready-to-use real-time PCR Mix 
SYBR® C (A&A Biotechnology) kit, pairs of specific primers (Genomed, 
Warszawa, Poland) for selected bacterial species and thermal amplifi-
cation programs were used (Table 1). The number of selected micro-
organisms was calculated per gram of stool by interpolating the cycle 
threshold (Ct) values obtained from the samples relative to appropriate 
standard calibration curve. 
2.4. Statistical analysis 
Descriptive statistics were calculated for quantitative variables. The 
intergroup differences of continuous variables not following normal 
distribution were assessed with the Kruskal–Wallis test. In the case of 
significant differences, post-hoc test was applied. The differences be-
tween pairs of observations (before and after treatment) were evaluated 
with the sign test. To determine the correlation between variables, the 
Spearman's rank correlation coefficient (R) was calculated. The p 
level < 0.05 was assumed to be statistically significant. Statistical 
analysis was carried out with the Statistica 13.1 software (StatSoft, Inc. 
Tulsa, Oklahoma, USA). 
3. Results 
We included 61 CD patients and 17 healthy children into the study. 
The characteristics of the study groups are presented in Table 2. 
There was a statistically significant decrease in PCDAI values after 
treatment in both EEN (p  <  0.001) and IFX (p  <  0.001) groups, 
which indicates a significant decrease in disease activity (Table 2). A 
total of 139 fecal samples (2 × 48 = 96 samples in the EEN group, 
2 × 13 = 26 in the IFX group and 17 in the control group) were 
quantitatively evaluated for the presence of bacterial DNA of selected 
bacterial species using qPCR. The results are presented in Table 3. 
The number of all tested bacteria changed during the treatment. 
However, statistically significant differences were found only in rela-
tion to two species: S. marcescens and L. fermentum. The number of S. 
marcescens was significantly lower both before (p  <  0.001) and after 
(p  <  0.001) the EEN in comparison to the control group. The number 
of L. fermentum at baseline was statistically higher (p = 0.001) in the 
IFX group from that in the controls. The number of these bacteria was 
also statistically significantly lower in the patients treated with IFX at 
the end of induction therapy compared to both the control group 
(p = 0.012) and patients before treatment (p = 0.013). In the group of 
children treated with EEN the number of L. fermentum after treatment 
increased and was statistically significantly higher from the number in 
the controls (p  <  0.001). Comparing both groups of patients (EEN vs. 
IFX), a statistically significant difference in the bacterial count was 
found only in the case of L. fermentum (p = 0.013) and only at the pre- 
treatment stage (4.55 × 109 CFU/g vs. 2.34 × 1010 CFU/g). 
There were no statistically significant differences in the number of 
B. fragilis and L. rhamnosus between the investigated groups of patients 
and controls at any time of the study. 
As for biochemical parameters, there was no statistically significant 
correlation, both before and after nutritional therapy between the 
number of selected bacterial species and glucose, protein, hemoglobin 
or C-reactive protein in the blood serum. Only in the IFX group, a po-
sitive correlation was observed between iron concentration and the 
number of B. fragilis both before (R = 0.56; p  <  0.05) and after 
(R = 0.64; p  <  0.05) therapeutic intervention. 
4. Discussion 
Numerous studies on CD etiology point to the changes of gut mi-
crobiota, although it is not clear whether the intestinal dysbiosis is the 
cause or the effect of inflammation in this disease [3,7,16,17]. It is 
Table 2 
Baseline data of the study groups.      
Characteristics EEN (n = 48) Biological therapy – IFX (n = 13) Control group (n = 17)  
Male:Female, n (%) 29 (60%):19 (40%) 7 (54%):6 (46%) 9 (53%):8 (47%) 
Age at diagnosis, years; mean (SD) 13.35 (3.09) 11.41 (4.01) N/A 
Age at initial treatment, years; mean (SD) 13.35 (3.09) 13.09 (3.76) 11.73 (SD  ±  2.88) †* 
Weight, kg; mean (SD) 40.93 (14.05) 41.97 (16.3) 42.8 (17.2) 
Height, cm; mean (SD) 155.3 (19.1) 149.95 (20.31) 148.7 (18.80) 
BMI, kg/m2; mean (SD) 16.4 (2.92) 17.89 (3.62) 18.3 (3.80) 
Pharmacological treatment 
CS, n 5 2 N/A 
AZA, n 42 9 N/A 
5-ASA, n 48 10 N/A 
MTX, n 0 2 N/A 
PCDAI-1, mean (SD) 32.03 (15.01) 47.5 (16.43) N/A 
PCDAI-2, mean (SD) 5.93 (11.36) 9.04 (6.50) N/A 
Biochemical parameters 
Glucose 1, mmol/l; mean (SD) 4.77 (0.86) 5.05 (0.88) N/A 
Glucose 2; mmol/l mean (SD) 4.62 (0.71) 5.0 (0.82) N/A 
Protein 1; g/l, mean (SD) 68.57 (7.5) 74.3 (7.39) N/A 
Protein 2; g/l, mean (SD) 75.96 (6.34) 78.65 (4.97) N/A 
Iron 1; umol/l mean (SD) 7.27 (5.7) 7.78 (3.44) N/A 
Iron 2; umol/l mean (SD) 11.96 (9.07) 8.46 (4.72) N/A 
Hgb 1, g/dl, mean (SD) 11.34 (1.91) 11.57 (1.87) N/A 
Hgb 2, g/dl, mean (SD) 12.82 (1.16) 11.99 (1.62) N/A 
CRP 1, mg/dl, mean (SD) 34.88 (35.36) 11.53 (11.41) N/A 
CRP 2, mg/dl, mean (SD) 8.13 (8.36) 8.13 (7.27) N/A 
†age at sampling 
*p-value for the comparison of age in the study groups  >  0.05 
Abbreviations: SD – standard deviation; EEN – exclusive enteral nutrition; IFX – infliximab; CS – corticosteroids; AZA – azathioprine; 5-ASA – mesalazine; MTX – 
methotrexate; PCDAI-1 – Pediatric Crohn's Disease Activity Index prior to therapeutic intervention; PCDAI-2 – Pediatric Crohn's Disease Activity Index after ther-
apeutic intervention; Glucose 1 – glucose concentration prior to therapeutic intervention; Glucose 2 - glucose concentration after therapeutic intervention; Protein 1 - 
protein concentration prior to therapeutic intervention; Protein 2 - protein concentration after therapeutic intervention; Iron 1 - iron concentration prior to ther-
apeutic intervention; Iron 2 – iron concentration after therapeutic intervention; Hgb 1- hemoglobin concentration prior to therapeutic intervention; Hgb 2- he-
moglobin concentration after therapeutic intervention; CRP 1 – C-reactive protein concentration prior to therapeutic intervention; CRP 2 - C-reactive protein 
concentration after therapeutic intervention.  
D. Salamon, et al.   Advances in Medical Sciences 65 (2020) 348–353
350
known that the balance between the Firmicutes, Gram-positive bacteria 
(e.g. depletion of Clades IV and XIVa Clostridia) and the Proteobacteria, 
Gram-negative bacteria (e.g. enrichment for the Enterobacteriaceae) 
and between Firmicutes and Gram-negative Bacteroidetes (including 
Bacteroides) is disturbed in CD. Different authors report both high and 
low Firmicutes/Bacteroidetes ratios [4,5,7,18]. These changes are also 
accompanied by a decrease in the biodiversity of intestinal microflora, 
which is observed in both luminal (fecal) and mucosal samples in pa-
tients with CD [7,17]. 
The role of Gram-negative anaerobic bacteria of the genus 
Bacteroides in the development of inflammation in the gastrointestinal 
tract is still investigated. Numerous studies indicate a decrease in the 
number of Bacteroides, including B. fragilis, in the course of CD [3,4], 
but there were also reports that those numbers are increasing [6,7]. 
Bacteria of the species B. fragilis produce polysaccharide A (PSA) which 
affects lymphocytes TReg producing anti-inflammatory cytokines (e.g. 
transforming growth factor beta - TGF-β or IL-10) which prevent the 
development of colitis [5]. However, Bloom et al. [19], demonstrated in 
a mouse model of IBD with human-relevant disease-susceptibility mu-
tations, that commensal Bacteroides species could induce colitis only in 
certain genetic or environmental contexts. B. fragilis, being an en-
terotoxigenic strain (ETBF), may be associated with IBD. Remacle et al. 
[20], demonstrated that potential virulence factors of ETBF i.e., en-
terotoxin (fragilysin) and secretory metalloproteinase II (MPII), weaken 
cell-to-cell contacts and adherence junctions of intestinal mucosal 
barrier. Most of the observations discussed above are the result of ex-
perimental animal models. In our present study, the number of B. fra-
gilis between the study groups did not differ significantly neither before 
nor after any type of treatment. Therefore, the relationship between this 
bacterium, CD and the treatment applied cannot be established on this 
basis. The observed positive correlation between the iron level and the 
number of B. fragilis is in line with numerous data indicating a strong 
dependence of this bacterium on heme, which in turn is conditioned by 
the iron level [21]. The presence of this correlation before and after the 
IFX treatment and the lack of significant correlations between iron le-
vels and the number of B. fragilis in the EEN group allows us to conclude 
that the effect of the type of therapy on this correlation cannot be de-
monstrated. 
S. marcescens is a Gram-negative bacterium belonging to the family 
Enterobacteriaceae, is commonly found in the environment and is also a 
possible source of nosocomial infections [12,22]. Its role in CD patho-
genesis is unclear. Using next-generation sequencing, Hoarau et al. [23] 
have shown a significant increase in the amount of S. marcescens in CD 
patients. In our study, we found the opposite relationship (i.e. sig-
nificantly smaller number of S. marcescens in the EEN group in com-
parison to the control group) but observed only in the EEN group. 
Perhaps this difference is related to the type of population studied 
(pediatric group with newly diagnosed CD and without the possibility 
of colonization of the gastrointestinal tract with bacteria from the 
hospital environment) or the implemented method to assess the bac-
terial count. To our knowledge, there is only one more study that in-
dicates the association of S. marcescens with CD and further research is 
needed. 
Many studies on gut microbiota in CD have focused on the Gram- 
positive Firmicutes bacteria of the genus Lactobacillus. Some authors 
reported a decrease while others observed an increase in the numbers of 
these microorganisms in the course of CD [17,18,24]. It may result from 
the fact that the genus Lactobacillus creates large groups of lactic acid 
bacteria (LAB), having more than 100 species. They are common in the 
environment and can sometimes have ambiguous effects on human 
health. LAB are also a part of oral and gastrointestinal microbiome, 
especially in breastfed infants. Certain species have probiotic properties 
[6,7,10,25]. In our study, we found no significant differences in the 
numbers of L. rhamnosus between the studied groups and the control 
group, which would suggest no direct influence of this bacterium on the 
course of CD. However, our analysis concerned L. rhamnosus globally as Ta
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a natural composition of the gut microbiota, while in many studies, the 
properties of this bacterium, as a specific, selected probiotic strain, have 
been evaluated for the use in the treatment of CD. There are many 
reports about the antimicrobial and anti-inflammatory effect of these 
bacteria, but there are also studies presenting inconclusive results 
[7,10,18]. However, our study focused primarily on the composition of 
the microbiome in health and disease, and did not analyze the ther-
apeutic properties of individual species. 
We also evaluated the second Lactobacillus species, which is con-
sidered to be a probiotic - L. fermentum - in the context of its con-
tribution to the development and course of CD [10,26]. To our 
knowledge, this is the first such analysis. It is interesting, however, that 
in the EEN group the number of L. fermentum slightly increased during 
the treatment, whereas in the IFX group, it significantly decreased. 
Several factors may lead to such results, including the initial pre- 
treatment status of children in each group, previous antibiotic therapy, 
and finally the treatment mode [2,3]. A larger number of L. fermentum 
in patients may suggest its involvement in the inflammatory process. 
Anderson et al. [27], have shown the role of the human oral isolate L. 
fermentum AGR1487 in the development of colitis in germ-free rats. 
Significantly higher numbers of L. fermentum in the IFX group than in 
the EEN group before treatment, as well as a significant decrease in the 
number of these bacteria in the IFX group after treatment and a de-
crease in disease activity expressed by a significant decrease in the 
PCDAI seem to confirm the hypothesis of proinflammatory activity of 
these bacteria. On the contrary, there are numerous studies indicating 
protective and immunomodulatory properties of L. fermentum in rela-
tion to colon mucosa [26,28]. This in turn is in line with high numbers 
of this species in the EEN group after treatment. We can speculate that a 
specific type of diet can contribute to this change [2,8]. However, the 
lack of precise determination of strains of this species of bacteria and 
their participation in the intestinal microbiota in our patients does not 
allow us to unequivocally explain the phenomenon described. Our re-
sults also suggest that bacterial strains of the same species can probably 
cause different host responses and highlight the importance of very 
precise strain characterization when considering the use of bacteria as 
probiotics in CD therapy. 
4.1. Limitations of the study 
As a limitation of our study we can mention that we have based only 
on fecal analysis, although we are aware that microbiome analysis in 
the tissue samples taken during biopsy would be a valuable addition to 
the study. However, to collect the biopsy, one needs to perform a co-
lonoscopy. It is an invasive procedure and in children the examination 
is usually performed under general anesthesia. Also, the standards of 
clinical care do not include routine colonoscopy after the nutritional 
treatment or IFX induction therapy. Similarly, due to the lack of pos-
sibility of microbiological analysis of biopsy, we decided not to assess 
the involvement of Escherichia coli (especially the mucosal-bound ad-
herent-invasive strain - AIEC). The role of this pathogen in IBD has been 
previously described in numerous studies [29,30], so we decided to 
choose those species of Gram-negative bacteria the role of which in this 
disease is unclear. The study covered selected bacterial species that 
were not representative of the whole microbiome. A comprehensive 
picture of changes in the microbiome could give the use of next-gen-
eration sequencing, but such analysis would only allow us to obtain 
percentage bacteria content, not absolute values as in our work. 
5. Conclusions 
Our observations are consistent with those of other authors and 
indicate that the composition of the microbiome varies between CD 
patients and healthy children. What is more, the implemented treat-
ment (EEN or IFX) modifies the microbiome in patients, but does not 
make it become the same as in healthy controls. An increase in the 
number of L. fermentum (which is considered to be a probiotic) in pa-
tients on EEN may suggest a link between this bacteria and the diet 
used. Adverse changes in the number of L. fermentum in patients treated 
with IFX are likely to be the result of the longer duration of the disease 
and the previously used treatment. 
The lack of unequivocal changes in the intestinal microbiome in the 
examined group of patients may also result from short observation time. 
We can speculate that the selected bacteria examined by us may 
contribute to the development of the disease process in CD. However, 
these findings prompt for further research with more precise tools that 
would allow not only for identification of bacterial strains, but also for 
determination of their role in Crohn's disease. 
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